13 drugs expected to be included in CMS negotiations: Study

Becker's Healthcare September 23, 2024
Alexandra Murphy

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027.

Researchers have aimed to predict which drugs would be selected by analyzing Part D spending from 2020 to 2022 and applying selection criteria from the Inflation Reduction Act and CMS guidelines.

The 13 drugs most likely to be chosen for CMS negotiations, according to the study:

1. Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk’s treatment for Type 2 diabetes and weight management.
2. Trelegy Ellipta (fluticasone/umeclidinium/vilanterol): A GlaxoSmithKline inhaler for chronic obstructive pulmonary disease.
3. Xtandi (enzalutamide): A prostate cancer treatment...

Today's Sponsors

Today's Sponsor